Oral delivery of therapeutically effective LNA oligonucleotides
The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.
1. A method for inhibiting miR-122 in the liver of a patient, comprising orally administering to a patient a composition comprising an LNA oligomer that targets miR-122 and a penetration enhancer, wherein the ratio between the penetration enhancer and LNA oligomer is at least 5:1 (w/w), and wherein the LNA oligomer is administered at less than 50 mg/kg.
2. The method of claim 1 wherein the LNA oligomer is between 8-16 nucleotides in length.
3. The method of claim 1 wherein the LNA oligomer is administered at an effective dose of less than 10 mg/kg.
4. The method of claim 1 wherein the oral administration is preceded by a parenteral pre-dose of the LNA oligomer, which is administered at least one day prior to the oral administration of the LNA oligomer.
5. The method of claim 1 wherein the oral administration is administered to maintain the concentration of the LNA oligomer in the patient's blood plasma between 0.04 nM and 25 nM.
6. The method of claim 1 wherein the oral administration is administered to maintain the concentration of the LNA oligomer in the patient's liver of between 10-100 μg/g.
7. The method of claim 1 wherein the LNA oligomer is orally administered at least once per week.
8. The method of claim 1 wherein the ratio of penetration enhancer to LNA oligomer is at least 10:1 (w/w).
9. The method of claim 1 wherein the penetration enhancer is selected from the group consisting of: a fatty acid, a bile acid, a chelating agent, an anionic cationic surfactant, and a non-chelating non-surfactant, or pharmaceutically acceptable salts thereof.